Anzeige
❌
Mehr »
Mittwoch, 21.10.2026 - Börsentäglich über 12.000 News
Lithium vor 2022. Kernkraft vor dem Comeback. Tiefseebergbau jetzt!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
370 Leser
Artikel bewerten:
(2)

Bioz, Inc.: Bioz and InvivoGen Elevate Scientific Discovery with an Expanded Digital Research Experience

PALO ALTO, CA / ACCESS Newswire / August 19, 2026 / Bioz, Inc., the scientific marketing platform that transforms peer-reviewed research into evidence-rich product experiences, is proud to announce the expansion of its longstanding partnership with InvivoGen, a leading provider of innovative tools for immunology, cell biology, and innate immune research.

For years, InvivoGen has leveraged Bioz solutions to connect researchers with peer-reviewed scientific evidence supporting its products. Building on this successful collaboration, InvivoGen has expanded its digital experience with the Bioz Content Hub: a centralized, standalone destination that brings relevant scientific publications together in one intuitive research environment.

The Bioz Content Hub gives researchers a powerful place to begin when they are exploring a new scientific question, application, or product category and are unsure where to start. Rather than searching across multiple sources, visitors can browse, search, and filter peer-reviewed publications featuring InvivoGen products, helping them identify relevant research and evaluate product use cases with greater confidence.

Once researchers identify the product best suited to their needs, the Content Hub connects them directly to the relevant InvivoGen product webpage with Bioz Badges present. This seamless path from publication discovery to product exploration helps reduce friction in the purchasing journey, allowing researchers to move efficiently from scientific evidence to an informed purchasing decision.

"Scientific literature plays a critical role in how researchers evaluate the tools they use in their work," said Annie Tiraby-Florette, Marketing Director at InvivoGen. "Our partnership with Bioz enables us to make that evidence more accessible and actionable. The Bioz Content Hub gives researchers an easy starting point for discovering publications relevant to their research, while creating a clear path to the InvivoGen products that can support their experiments."

The Bioz Content Hub is continuously updated as new peer-reviewed research becomes available, ensuring that scientists have access to the latest publications featuring InvivoGen technologies. Early engagement across InvivoGen's research content has already been impressive, demonstrating that researchers value a centralized, evidence-rich resource for exploring scientific applications and product validation.

"Making it easier for researchers to find the right information at the right time has been an important focus of our digital strategy," said Emmanuel Gardette, Webmaster at InvivoGen. "We are very encouraged by the early engagement we are seeing across our research content. The Bioz Content Hub provides a streamlined and intuitive experience where visitors can discover scientific evidence and quickly navigate to the products they need."

"InvivoGen has been a valued Bioz partner, and we are excited to see them expand their use of our platform with the Bioz Content Hub," said Dr. Karin Lachmi, Co-Founder and Chief Revenue Officer at Bioz. "The strong early engagement with their research content reinforces the value of making peer-reviewed scientific evidence easy to discover. Together, we are helping scientists move from questions to validated product decisions more efficiently."

About Bioz

Bioz is the world's most advanced citation-based data platform for scientific research, offering evidence-backed product ratings and recommendations to guide scientists toward the most validated products and services for their discoveries. Bioz's solutions for suppliers include Bioz Badges and Bioz Content Hubs, web-based widgets that enhance user engagement and increase sales conversion.

About InvivoGen

InvivoGen is a global provider of innovative research tools that support scientists working in immunology, cell biology, molecular biology, and related life science fields. The company offers a broad portfolio of products, including innate immune receptor ligands, reporter cell lines, recombinant proteins, antibodies, plasmids, selection antibiotics, and cell culture reagents. By developing high-quality, reliable tools for studying immune signaling pathways and cellular function, InvivoGen helps researchers advance discoveries in areas such as infectious disease, cancer, inflammation, vaccine development, and immunotherapy.

Helpful Links

  • Bioz

  • Bioz Badges

  • Bioz Stars

  • InvivoGen

For more information about Bioz solutions for suppliers, please reach out to info@bioz.com.

SOURCE: Bioz, Inc.



View the original press release on ACCESS Newswire:
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/bioz-and-invivogen-elevate-scientific-discovery-with-an-expanded-digi-1204658

© 2026 ACCESS Newswire
KI-Euphorie kippt - Bei diesen 5 Aktien droht der Crash!
Drei Jahre lang kannten KI-Aktien fast nur eine Richtung: nach oben. Billionenschwere Investitionspläne von Alphabet, Amazon, Meta und Microsoft haben Halbleiter- und Infrastrukturwerte auf immer neue Höhen getrieben. Doch jetzt bekommt die Erfolgsstory gefährliche Risse.

Steigende Anleiherenditen verteuern die Finanzierung, während die gewaltigen KI-Ausgaben zunehmend nicht mehr aus den laufenden Cashflows bezahlt werden können. Gleichzeitig zeigen günstigere chinesische Modelle, dass leistungsfähige KI womöglich mit deutlich weniger Rechenleistung auskommt. Damit wächst die Gefahr, dass heute für Milliarden errichtete Kapazitäten morgen nicht die erhofften Renditen liefern.

Für Anleger könnte das zum Problem werden. Denn treffen steigende Finanzierungskosten auf Überkapazitäten und enttäuschende Cashflows, geraten gerade hoch bewertete KI-Profiteure schnell unter Druck. Aus den größten Gewinnern der vergangenen Jahre könnten so die größten Verlierer der nächsten Korrektur werden.

In unserem aktuellen Spezialreport zeigen wir 5 Aktien, bei denen das Chance-Risiko-Verhältnis jetzt besonders gefährlich erscheint – und bei denen Anleger genauer hinschauen sollten.

Jetzt den kostenlosen Report sichern – bevor die KI-Euphorie ihren nächsten Realitätstest erlebt!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.